参考文献/References:
[1].Charlton A,Garzarella J,Jandeleit-Dahm KAM,et al. Oxidative stress and inflammation in renal and cardiovascular complications of diabetes[J].?Biology,2020,10(1):18.
[2].Galicia-Garcia U,Benito-Vicente A,Jebari S,et al. Pathophysiology of type 2 diabetes mellitus[J].?Int J Mol Sci,2020,21(17):6275.
[3].Recchiuti A,Mattoscio D,Isopi E. Roles,actions,and therapeutic potential of specialized pro-resolving lipid mediators for the treatment of inflammation in cystic fibrosis[J].?Front Pharmacol,2019,10:252.
[4].Climax J,Newsome PN,Hamza M,et al. Effects of epeleuton,a novel synthetic second-generation n-3 fatty acid,on non-alcoholic fatty liver disease,triglycerides,glycemic control,and cardiometabolic and inflammatory markers[J]. J Am Heart Assoc,2020,9(16):e016334.
[5].Duan J,Song Y,Zhang X,et al. Effect of ω-3 polyunsaturated fatty acids-derived bioactive lipids on metabolic disorders[J] .?Front Physiol,2021,12:646491.
[6].Perez-Hernandez J,Chiurchiù V,Perruche S,et al. Regulation of T-cell immune responses by pro-resolving lipid mediators[J].?Front Immunol,2021,12:768133.
[7].Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology[J].?Mol Aspects Med,2017,58:1-11.
[8].Park J,Langmead CJ,Riddy DM. New advances in targeting the resolution of inflammation:implications for specialized pro-resolving mediator GPCR drug discovery[J].?ACS Pharmacol Transl Sci,2020,3(1):88-106.
[9].Souza PR,Marques RM,Gomez EA,et al. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses:a randomized double-blind placebo-controlled study[J]. Circ Res,2020,126(1):75-90.
[10].de Gaetano M,McEvoy C,Andrews D,et al. Specialized pro-resolving lipid mediators:modulation of diabetes-associated cardio-,reno-,and retino-vascular complications[J].?Front Pharmacol,2018,9:1488.
[11].Beverly JK,Budoff MJ. Atherosclerosis:pathophysiology of insulin resistance,hyperglycemia,hyperlipidemia,and inflammation[J]. J Diabetes,2020,12(2):102-104.
[12].Bays HE,Taub PR,Epstein E,et al. Ten things to know about ten cardiovascular disease risk factors[J].?Am J Prev Cardiol,2021,5:100149.
[13].Brennan EP,Mohan M,McClelland A,et al.Lipoxins protect against inflammation in diabetes-associated atherosclerosis[J].Diabetes,2018,67(12):2657-2667.
[14].Yuan T,Yang T,Chen H,et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis[J]. Redox Biol,2019,20:247-260.
[15].Brennan E,Wang B,McClelland A,et al. Protective effect of let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis[J]. Diabetes,2017,66(8):2266-2277.
[16].Fredman G,Tabas I. Boosting inflammation resolution in atherosclerosis:the next frontier for therapy[J]. Am J Pathol,2017,187(6):1211-1221.
[17].Brennan E,Kantharidis P,Cooper ME,et al. Pro-resolving lipid mediators:regulators of inflammation,metabolism and kidney function[J]. Nat Rev Nephrol,2021,17(11):725-739.
[18].Brennan EP,Mohan M,McClelland A,et al. Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease[J].J Am Soc Nephrol,2018,29(5):1437-1448.
[19].Sifuentes-Franco S,Padilla-Tejeda DE,Carrillo-Ibarra S.?Oxidative stress,apoptosis,and mitochondrial function in diabetic nephropathy[J].?Int J Endocrinol,2018,2018:1875870.
[20].Roh J,Go EJ,Park JW,et al. Resolvins:potent pain inhibiting lipid mediators via transient receptor potential regulation[J].?Front Cell Dev Biol,2020,8:584206.
[21].Perazza LR,Mitchell PL,Lizotte F,et al. Fish oil replacement prevents,while docosahexaenoic acid-derived protectin DX mitigates end-stage-renal-disease in atherosclerotic diabetic mice[J].?FASEB J,2021,35(5):e21559.
[22].Bai Y,Wang J,He Z,et al. Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines [J]. Med Sci Monit,2019,25:3069-3076.
[23].Qiu X,Wang X,Hong P,et al. Retinal blood oxygen saturation and vascular endothelial growth factor-A in early diabetic retinopathy:a protocol for systematic review and meta-analysis[J].?Medicine (Baltimore),2020,99(24):e20562.
[24].Storti F,Pulley J,Kuner P,et al. Circulating biomarkers of inflammation and endothelial activation in diabetic retinopathy[J].?Transl Vis Sci Technol,2021,10(12):8.
[25].Rubsam A,Parikh S,Fort PE. Role of inflammation in diabetic retinopathy[J].?Int J Mol Sci,2018,19(4):942.
[26].Yin Y,Chen F,Wang W,et al.?Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats:possible involvement of NLRP3 inflammasome and NF-kappaB signaling pathway[J].?Mol Vis,2017,23:242-250.
[27].Le YZ,Xu B,Chucair-Elliott AJ,et al. VEGF mediates retinal müller cell viability and neuroprotection through BDNF in diabetes[J]. Biomolecules,2021,11(5):712.
[28].Platania CBM,Maisto R,Trotta MC,et al. Retinal and circulating miRNA expression patterns in diabetic retinopathy:An in silico and in vivo approach[J]. Br J Pharmacol,2019,176(13):2179-2194.
[29].Dobrian AD,Morris MA,Taylor-Fishwick DA,et al. Role of the 12-lipoxygenase pathway in diabetes pathogenesis and complications[J].?Pharmacol Ther,2019,195:100-110.
[30].Coppey L,Davidson E,Shevalye H,et al. Progressive loss of corneal nerve fibers and sensitivity in rats modeling obesity and type 2 diabetes is reversible with omega-3 fatty acid intervention:supporting cornea analyses as a marker for peripheral neuropathy and treatment[J].?Diabetes Metab Syndr Obes,2020,13:1367-1384.
[31].Ye D,Fairchild TJ,Vo L,et al. Painful diabetic peripheral neuropathy:role of oxidative stress and central sensitisation[J]. Diabet Med,2022,39(1):e14729.
[32].Sharma A,Mah M,Ritchie RH,et al.The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?[J]. Pharmacol Ther,2021,108008.
[33].Wu SH,Chen XQ,Liu B,et al. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema[J]. Br J Dermatol,2013,108(1):172-178.
[34].Basil MC,Levy BD. Specialized pro-resolving mediators:endogenous regulators of infection and inflammation[J].?Nat Rev Immunol,2016,16(1):51-67.
[35].Serhan CN,Chiang N,Dalli J. The resolution code of acute inflammation:Novel pro-resolving lipid mediators in resolution[J].?Semin Immunol,2015,27(3):200-215.